Loading...
•
Mar 31, 2024
BioCryst Q1 2024 Earnings Report
BioCryst reported Q1 2024 financial results with ORLADEYO net revenue growing 30 percent year-over-year.
Key Takeaways
BioCryst's Q1 2024 total revenues reached $92.8 million, driven by ORLADEYO net revenue of $88.9 million, a 30% increase year-over-year. The company is increasing its revenue guidance for 2024.
ORLADEYO net revenue grew 30 percent year-over-year to $88.9 million.
Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million.
Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, are advancing on schedule into clinical trials.
The company expects total cash at the end of 2024 will be above $300 million.
Revenue by Segment
Forward Guidance
BioCryst has adjusted its outlook for full year 2024 global net ORLADEYO revenue to be between $390 million and $400 million and expects full year 2024 operating expenses to be between $365 million and $375 million.
Positive Outlook
- Full year 2024 global net ORLADEYO revenue to be between $390 million and $400 million
- Achieve a full-year operating profit in 2024 (not including non-cash stock compensation)
- Approaching quarterly positive earnings per share (EPS) and positive cash flow in the second half of 2025 (not including non-cash stock compensation)
- Be profitable on an EPS basis, with positive cash flow, for full year 2026
- The company expects it can achieve these financial milestones without raising additional funds and does not intend to draw the additional $150 million of debt available to it from Pharmakon.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...